Paul A Beavis

List of Publications by Year in Descending Order

61 papers	5,046 citations	32 h-index	71 g-index
72 ext. papers	6,850 ext. citations	14.2 avg, IF	5.55 L-index

#	Paper	IF	Citations
61	Differential location of NKT and MAIT cells within lymphoid tissue.. *Scientific Reports*, **2022**, 12, 4034	4.9	0
60	Challenges of Creating New Tumor-Infiltrating Lymphocyte for Combating Breast Cancer.. *Journal of Clinical Oncology*, **2022**, JCO2200284	2.2	
59	Adoptive transfer of tumor-specific Th9 cells eradicates heterogeneous antigen-expressing tumor cells. *Cancer Cell*, **2021**,	24.3	3
58	PTP1B is an intracellular checkpoint that limits T cell and CAR T cell anti-tumor immunity. *Cancer Discovery*, **2021**,	24.4	3
57	Augmenting Adoptive T-cell Immunotherapy by Targeting the PD-1/PD-L1 Axis. *Cancer Research*, **2021**, 81, 5803-5805	10.1	0
56	Cellular networks controlling T cell persistence in adoptive cell therapy. *Nature Reviews Immunology*, **2021**, 21, 769-784	36.5	17
55	CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. *Nature Communications*, **2021**, 12, 3236	17.4	22
54	Myeloma natural killer cells are exhausted and have impaired regulation of activation. *Haematologica*, **2021**, 106, 2522-2526	6.6	2
53	CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory. *Cancer Discovery*, **2021**, 11, 2582-2601	24.4	12
52	The role of exhaustion in CAR T cell therapy. *Cancer Cell*, **2021**, 39, 885-888	24.3	5
51	MAIT cells regulate NK cell-mediated tumor immunity. *Nature Communications*, **2021**, 12, 4746	17.4	8
50	Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. *Nature Immunology*, **2020**, 21, 914-926	19.1	53
49	p38 Kinase: A Key Target for Driving Potent T Cells for Adoptive Immunotherapy. *Cancer Cell*, **2020**, 37, 756-758	24.3	0
48	Promising Immuno-Oncology Options for the Future: Cellular Therapies and Personalized Cancer Vaccines. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2020**, 40, 1-6	7.1	5
47	Efficient CRISPR/Cas9 Gene Editing in Uncultured Naive Mouse T Cells for In Vivo Studies. *Journal of Immunology*, **2020**, 204, 2308-2315	5.3	12
46	Sex-specific adipose tissue imprinting of regulatory T cells. *Nature*, **2020**, 579, 581-585	50.4	72
45	Tissue-resident memory T cells in breast cancer control and immunotherapy responses. *Nature Reviews Clinical Oncology*, **2020**, 17, 341-348	19.4	70

44	A New Safety Approach Allowing Reversible Control of CAR T Cell Responses. *Molecular Therapy*, **2020**, 28, 1563-1566	11.7	
43	PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours. *EMBO Journal*, **2020**, 39, e103637	13	36
42	IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors. *Molecular Therapy*, **2020**, 28, 2379-2393	11.7	19
41	Pharmacological and genetic strategies for targeting adenosine to enhance adoptive T cell therapy of cancer. *Current Opinion in Pharmacology*, **2020**, 53, 91-97	5.1	1
40	Targeting the epigenetic regulation of antitumour immunity. *Nature Reviews Drug Discovery*, **2020**, 19, 776-800	64.1	81
39	Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion. *Cancer Research*, **2020**, 80, 4129-4144	10.1	19
38	Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. *Clinical Cancer Research*, **2020**, 26, 487-504	12.9	138
37	An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. *Cancer Cell*, **2019**, 36, 385-401.e8	24.3	169
36	Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression. *Science Translational Medicine*, **2019**, 11,	17.5	65
35	Switching on the green light for chimeric antigen receptor T-cell therapy. *Clinical and Translational Immunology*, **2019**, 8, e1046	6.8	9
34	Tissue-specific tumor microenvironments influence responses to immunotherapies. *Clinical and Translational Immunology*, **2019**, 8, e1094	6.8	11
33	Antagonism of IAPs Enhances CAR T-cell Efficacy. *Cancer Immunology Research*, **2019**, 7, 183-192	12.5	33
32	Tumor-derived exosomes modulate T cell function through transfer of RNA. *FEBS Journal*, **2018**, 285, 1030-1032	5.7	4
31	Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E2068-E2076	11.5	129
30	Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4Foxp3 Cell-Mediated Modulation of CD103 Dendritic Cells. *Cancer Immunology Research*, **2018**, 6, 1069-1081	12.5	38
29	Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. *Nature Medicine*, **2018**, 24, 986-993	50.5	420
28	Targeting Adenosine Receptor Signaling in Cancer Immunotherapy. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	90
27	Tumor immune evasion arises through loss of TNF sensitivity. *Science Immunology*, **2018**, 3,	28	119

26	A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells. *Cancer Research*, **2017**, 77, 1296-1309	10.1	46
25	BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. *Cell Reports*, **2017**, 18, 2162-2174	10.6	170
24	A novel combination strategy for effectively targeting cancer stem-like cells. *Immunology and Cell Biology*, **2017**, 95, 573-574	5	3
23	Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. *Clinical Cancer Research*, **2017**, 23, 2478-2490	12.9	71
22	T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin\ Lymphoma. *OncoImmunology*, **2017**, 7, e1365997	7.2	1
21	Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. *Nature Communications*, **2017**, 8, 606	17.4	60
20	A Novel Target Antigen for the Treatment of Acute Myeloid Leukemia by CAR T Cells. *Molecular Therapy*, **2017**, 25, 1997-1998	11.7	2
19	CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. *Nature*, **2017**, 549, 101-105	38.4	375
18	Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. *Journal of Clinical Investigation*, **2017**, 127, 929-941	15.9	183
17	Reprogramming the tumor microenvironment to enhance adoptive cellular therapy. *Seminars in Immunology*, **2016**, 28, 64-72	10.7	41
16	RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. *Clinical Cancer Research*, **2016**, 22, 1499-509	12.9	311
15	Immunosuppressive activities of adenosine in cancer. *Current Opinion in Pharmacology*, **2016**, 29, 7-16	5.1	156
14	Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression. *Immunotherapy*, **2015**, 7, 499-512	3.8	16
13	Relevance of tumor-infiltrating lymphocytes in breast cancer. *BMC Medicine*, **2015**, 13, 202	11.4	131
12	CD73: A potential biomarker for anti-PD-1 therapy. *OncoImmunology*, **2015**, 4, e1046675	7.2	23
11	Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses. *Cancer Immunology Research*, **2015**, 3, 506-17	12.5	198
10	CD3bright signals on T cells identify IL-17A-producing V6V1+ T cells. *Immunology and Cell Biology*, **2015**, 93, 198-212	5	50
9	Cross-talk between tumors can affect responses to therapy. *OncoImmunology*, **2015**, 4, e975572	7.2	7

8	CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 11091-6	11.5	303
7	A blockade enhances anti-metastatic immune responses. *OncoImmunology*, **2013**, 2, e26705	7.2	13
6	Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 14711-6	11.5	244
5	Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. *Clinical Cancer Research*, **2013**, 19, 5636-46	12.9	485
4	CD73-deficient mice are resistant to carcinogenesis. *Cancer Research*, **2012**, 72, 2190-6	10.1	156
3	CD73: a potent suppressor of antitumor immune responses. *Trends in Immunology*, **2012**, 33, 231-7	14.4	253
2	Activation of p38 mitogen-activated protein kinase is critical step for acquisition of effector function in cytokine-activated T cells, but acts as a negative regulator in T cells activated through the T-cell receptor. *Immunology*, **2011**, 132, 104-10	7.8	18
1	Resistance to regulatory T cell-mediated suppression in rheumatoid arthritis can be bypassed by ectopic foxp3 expression in pathogenic synovial T cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 16717-22	11.5	43